U.S. markets open in 5 hours 35 minutes
  • S&P Futures

    4,394.00
    +14.25 (+0.33%)
     
  • Dow Futures

    34,866.00
    +145.00 (+0.42%)
     
  • Nasdaq Futures

    14,983.25
    +30.50 (+0.20%)
     
  • Russell 2000 Futures

    2,224.00
    +13.10 (+0.59%)
     
  • Crude Oil

    71.41
    +0.15 (+0.21%)
     
  • Gold

    1,813.30
    -8.90 (-0.49%)
     
  • Silver

    25.36
    -0.22 (-0.84%)
     
  • EUR/USD

    1.1885
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.1740
    0.0000 (0.00%)
     
  • Vix

    18.85
    +0.61 (+3.34%)
     
  • GBP/USD

    1.3919
    +0.0036 (+0.26%)
     
  • USD/JPY

    109.1960
    -0.1130 (-0.10%)
     
  • BTC-USD

    38,538.90
    -1,562.49 (-3.90%)
     
  • CMC Crypto 200

    936.27
    -24.63 (-2.56%)
     
  • FTSE 100

    7,108.91
    +27.19 (+0.38%)
     
  • Nikkei 225

    27,641.83
    -139.19 (-0.50%)
     

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

·2 min read

SEATTLE, April 21, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on April 21, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received options to purchase an aggregate of 80,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
cti@argotpartners.com

CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)
CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301274447.html

SOURCE CTI BioPharma Corp.